DOCSLIB.ORG

PDM Drug Chart Brochure 0315 Web

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PDM Drug Chart Brochure 0315 Web Prescription Drug Monitoring Profiles 906253 906258 706263 906249 906254 906259 906507 906508 Base Prole Profile 1 Profile 1 Profile 1 w/Conrmation w/Conrmation Base Profile Base Profile w/Conrmation Profile 1 Profile 1 w/D/L Isomers w/ Conrmation w/medMATCHTM w/Conrmation w/o Conrmation w/medMATCHTM w/Conrmation w/o Conrmation w/medMATCHTM w/ D/L Isomers Amphetamines • • • • • Barbiturates • • • • • Benzodiazepines • • • • • • • • Cocaine • • • • • • • • Marijuana • • • • • Methadone • • • • • Opiates • • • • • • • • Oxycodone • • • • • • • • Phencyclidine • • • • • Individual components are orderable separately. Please refer to our Prescription Drug Monitoring laboratory request form or the Prescription Drug Monitoring section of our Reference Manual. For assistance with interpreting Prescription Drug Monitoring Results, please contact a Toxicology Specialist at 1-877-40-RX TOX (1-877-407-9869), M–F 8am to 6pm EST. SonoraQuest.com Sonora Quest Laboratories, any associated logos, and all associated Sonora Quest Laboratories registered or unregistered trademarks are the property of Sonora Quest Laboratories. All third party marks - ® and ™ - are the property of their respective owners. © 2015 Sonora Quest Laboratories. All rights reserved. 3/2015 QuestDiagnostics.com Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks - ® and ™ - are the property of their respective owners. © 2015 Quest Diagnostics. All rights reserved. 3/2015 TM ® #1 Bioscience Firm 2015 0315 TM Prescription Drug Monitoring Reference Guide Source of Drug Metabolite Mass Initial Additiona l Screen Spectrometry Urine Screen Drug Quantitations/ Metabolites / Common Trade / Drug/Drug Class Method of Generic Name Quantitative/ Detection Cuto Confirmations Compound s Street Name Analysis Confirmation Time Often Present (ng/mL) Cuto (ng/mL) Alcohol Metabolites LC-MS/MS 500 1-3 Days Ethyl Sulfate (EtS) Ethyl 100 Glucuronide (EtG) Amphetamine None Amphetamine Adderall®, Dexedrine®, Dextrostat®, 250 Amphetamines EIA 500 Vyvanse® 1-3 Days Methamphetamine Amphetamine Methamphetamine Desoxyn® 250 Amphetamine None Amphetamine Adderall®, Dexedrine®, Dextrostat®, 250 Vyvanse® Amphetamines with Methamphetamine d/l EIA 500 Methamphetamine Amphetamine Methamphetamine Desoxyn® 250 1-3 Days Isomers d-Methamphetamine None d-Methamphetamine Desoxyn® 250 l-Methamphetamine None l-Methamphetamine Vicks Inhaler®, Selegiline® 250 Amobarbital (Secobarbital Amobarbital Amytal® 100 Combination) Tuinal® - (Amobarbital/ Secobarbital Combination) Butalbital None Butalbital Esgic®, Fioricet®, Fiorinal®, Sandoptal® 100 1-3 Days Short Barbiturates EIA 300 Acting; >3 Long Pentobarbital None Pentobarbital Nembutal® 100 Acting Secobarbital (Amobarbital Secobarbital Seconal®, Tuinal® - (Amobarbital/ 100 Combination) Secobarbital Combination) Phenobarbital None Phenobarbital Luminal® 100 For assistance with interpreting Prescription Drug Monitoring Results, please contact a Toxicology Specialist at 1-877-40-RX TOX (1-877-407-9869), M–F 8am to 6pm EST. Source of Drug Metabolite Mass Initial Additiona l Screen Spectrometry Urine Screen Drug Quantitations/ Metabolites / Common Trade / Drug/Drug Class Method of Generic Name Quantitative/ Detection Cuto Confirmations Compound s Street Name Analysis Confirmation Time (ng/mL) Often Present Alphahydroxyalprazolam None Alprazolam Xanax® 25 Alphahydroxymidazolam None Midazolam Versed® 50 Alphahydroxytriazolam None Triazolam Halcion® 50 Aminoclonazepam None Clonazepam Klonopin® 25 Hydroxyethylflurazepam None Flurazepam Dalmane® 50 Lorazepam None Lorazepam Ativan® 50 1-3 Days Short Nordiazepam Oxazepam, Chlordiazepoxide, Chlordiazepoxide - Librium®, 50 Benzodiazepines EIA 100 Acting; >3 Long Temazepam Clorazepate, Clorazepate - Tranxene®, Acting Diazepam Diazepam - Valium® Oxazepam Nordiazepam, Temazepam Chlordiazepoxide, Chlordiazepoxide - Librium®, 50 Clorazepate, Diazepam, Clorazepate - Tranxene®, Oxazepam, Temazepam Diazepam - Valium®, Oxazepam - Librax®, Serax®, Temazepam - Restoril® Temazepam Oxazepam, Nordiazepam Diazepam, Temazepam Restoril®, Valium® 50 Buprenorphine Norbuprenorphine 2 Buprenorphine EIA 5 Buprenorphine Suboxone®, Subutex® 1-3 Days Norbuprenorphine None 2 Carisoprodol Meprobamate None Carisoprodol Soma®, Equagesic® 1000 1-3 Days Cocaine Metabolite EIA 150 Benzoylecgonine None Cocaine Coke 100 1-3 Days Fentanyl Norfentanyl Abstral®, Actiq®, Duragesic®, 0.5 Fentanyl Fentanyl 1-2 Days Norfentanyl None Fentora®, Ionsys® 0.5 Gabapentin Gabapentin None Gabapentin Fanatrex, Gabarone, Neurontin 1000 1-3 Days Heroin Metabolite EIA 10 6-Acetylmorphine None Heroin Heroin 10 1 Day Marijuana Metabolite EIA 20 Marijuana Metabolite None Marijuana Marinol®, Dronabinol® 5 1-3 Days Casual Use; >3 Chronic Use MDA None MDA Ecstasy, Sally 200 MDMA/MDA EIA 500 1-2 Days MDMA MDA MDMA Ecstasy 200 Meperidine Normeperidine 100 Meperidine Meperidine Demerol® 1-3 Days Normeperidine None 100 Methadone EDDP 100 Methadone Metabolite EIA 100 Methadone Dolophine® 1-3 Days EDDP None 100 Source of Drug Metabolite Mass Initial Additional Screen Spectrometry Urine Screen Drug Quantitations/ Metabolites / Common Trade / Drug/Drug Class Method of Generic Name Quantitative/ Detection Cuto Confirmations Compounds Street Name Analysis Time (ng/mL) Often Present Confirmation Cuto (ng/mL) d-Methamphetamine None d-Methamphetamine Desoxyn® 250 Methamphetamine d/l Isomers 1-3 Days l-Methamphetamine None l-Methamphetamine Vicks Inhaler®, Selegiline® 250 Methylphenidate Ritalinic Acid None Methylphenidate Ritalin®, Concerta® 100 1-3 Days Codeine Morphine Codeine Tylenol #3®, Tylenol #4®, Tylenol w/ 50 (Hydrocodone - Codeine®, Acetaminophen w/ Codeine®, Minor Metabolite) Phenaphen w/ Codeine®, Phenergan w/ Codeine®, Phenameth w/ Codeine®, Promethazine w/ Codeine® Morphine (Hydromorphone - Morphine Avinza®, Kadian®, 50 Opiates EIA 100 Minor Metabolite) MS Contin®, Roxanol® 1-3 Days Hydrocodone Hydromorphone, Hydrocodone Hycodan®, Lorcet®, Lortab®, Norco®, 50 Norhydrocodone Vicodin® Hydromorphone None Hydromorphone Dilaudid® 50 Norhydrocodone Hydromorphone Hydrocodone Hycodan®, Lorcet®, Lortab®, Norco®, 50 Vicodin® Noroxycodone Oxycodone, Endocet®, Magnacet®, OxyContin®, 50 Oxymorphone OxyFAST®, OxyIR®, Percocet®, Oxycodone Oxycodone EIA 100 Oxycodone Noroxycodone, Percodan®, Perolox®, Roxicet®, 50 1-3 Days Oxymorphone Roxicodone®, Tylox® Oxymorphone None Oxymorphone Opana®, Numorphan® 50 Phencyclidine EIA 25 Phencyclidine None Phencyclidine PCP 25 1-3 Days Pregabalin Pregabalin None Pregabalin Lyrica® 1000 1-3 Days Tapentadol Nortapentadol 50 Tapentadol Tapentadol Nucynta® 1-3 Days Nortapentadol None 50 Tramadol Desmethyltramadol 100 Tramadol Tramadol Rybix®, Ryzolt®, Ultram® 1-3 Days Desmethyltramadol None 100 Amitriptyline Nortriptyline Amitriptyline, Elavil® 100 Tricyclic Antidepressants Nortriptyline 1-3 Days Nortriptyline None Nortriptyline Aventyl®, Pamelor® 100 Source of Drug Metabolite Mass Initial Additiona l Screen Spectrometry Urine Screen Drug Quantitations/ Metabolites / Common Trade / Drug/Drug Class Method of Generic Name Quantitative/ Detection Cuto Confirmations Compound s Street Name Analysis Confirmation Time (ng/mL) Often Present Alphahydroxyalprazolam None Alprazolam Xanax® 25 Alphahydroxymidazolam None Midazolam Versed® 50 Alphahydroxytriazolam None Triazolam Halcion® 50 Aminoclonazepam None Clonazepam Klonopin® 25 Hydroxyethylflurazepam None Flurazepam Dalmane® 50 Lorazepam None Lorazepam Ativan® 50 1-3 Days Short Nordiazepam Oxazepam, Chlordiazepoxide, Chlordiazepoxide - Librium®, 50 Benzodiazepines EIA 100 Acting; >3 Long Temazepam Clorazepate, Clorazepate - Tranxene®, Acting Diazepam Diazepam - Valium® Oxazepam Nordiazepam, Temazepam Chlordiazepoxide, Chlordiazepoxide - Librium®, 50 Clorazepate, Diazepam, Clorazepate - Tranxene®, Oxazepam, Temazepam Diazepam - Valium®, Oxazepam - Librax®, Serax®, Temazepam - Restoril® Temazepam Oxazepam, Nordiazepam Diazepam, Temazepam Restoril®, Valium® 50 Buprenorphine Norbuprenorphine 2 Buprenorphine EIA 5 Buprenorphine Suboxone®, Subutex® 1-3 Days Norbuprenorphine None 2 Carisoprodol Meprobamate None Carisoprodol Soma®, Equagesic® 1000 1-3 Days Cocaine Metabolite EIA 150 Benzoylecgonine None Cocaine Coke 100 1-3 Days Fentanyl Norfentanyl Abstral®, Actiq®, Duragesic®, 0.5 Fentanyl Fentanyl 1-2 Days Norfentanyl None Fentora®, Ionsys® 0.5 Gabapentin Gabapentin None Gabapentin Fanatrex, Gabarone, Neurontin 1000 1-3 Days Heroin Metabolite EIA 10 6-Acetylmorphine None Heroin Heroin 10 1 Day Marijuana Metabolite EIA 20 Marijuana Metabolite None Marijuana Marinol®, Dronabinol® 5 1-3 Days Casual Use; >3 Chronic Use MDA None MDA Ecstasy, Sally 200 MDMA/MDA EIA 500 1-2 Days MDMA MDA MDMA Ecstasy 200 Meperidine Normeperidine 100 Meperidine Meperidine Demerol® 1-3 Days Normeperidine None 100 Methadone EDDP 100 Methadone Metabolite EIA 100 Methadone Dolophine® 1-3 Days EDDP None 100 Source of Drug Metabolite Mass Initial Additional Screen Spectrometry Urine Screen Drug Quantitations/ Metabolites / Common Trade / Drug/Drug Class Method of Generic Name Quantitative/ Detection Cuto Confirmations Compounds Street Name Analysis Time (ng/mL) Often Present Confirmation Cuto (ng/mL) d-Methamphetamine None d-Methamphetamine Desoxyn® 250 Methamphetamine d/l Isomers 1-3 Days l-Methamphetamine None l-Methamphetamine Vicks Inhaler®, Selegiline® 250 Methylphenidate Ritalinic Acid None Methylphenidate Ritalin®, Concerta® 100 1-3 Days Codeine
Load more

Recommended publications
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • Quest Diagnostics Prescription Drug Monitoring Reference Guide
    Clinical Drug Monitoring Reference Guide Clinical Drug Monitoring Test List with Test Codes Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Cocaine Metabolite 92225 70248 16888 90082 16916 Naltrexone 93753 Amphetamines 92222 70245 16885 70209 16913 Eszopiclone 91251 Opiates 92230 18991 16891 70237* 16298* Amphetamines Fentanyl 36278 36279 36280 18996 16900 Oxycodone 92231 18992 16892 70238 16920 91590 91589 92484 92483 with Reflex d/l Isomers Gabapentin 70205 16904 Phencyclidine 92232 18993 16893 90083 16921 Antidepressants (urine) 94032 Heroin Metabolite 92226 90081 16911 90333 90329 Pregabalin 70208 16908 Antidepressants (serum) 94031 Marijuana Metabolite 92227 18989 16889 70233 16917 Propoxyphene 92233 18995 16894 70239 16922 Antipsychotics (urine) 94528 MDMA/MDA 92228 90078 16909 90334 90331 Synthetic Cannabinoids 93027 Antipsychotics (serum) 94529 Meperidine 70206 16905 Synthetic Stimulants 90322 Barbiturates 92223 70246 16886 70230 16912 Methadone Metabolite 92229 18990 16890 70234 16918 Tapentadol 90244 90243 Benzodiazepines 92224 70247 16887 70231 16914 Methamphetamine Tramadol 70207 16906 90319 Buprenorphine 16207 70249 16901 18998 16213 d/l Isomers Tricyclic Antidepressants 70204 16903 Buprenorphine 93093 93094 Methylphenidate 90247 90246 with Naloxone Zolpidem 91258 Mitragynine 39241 39240 Carisoprodol 18999 16902 *Includes oxycodone drug class Test Profiles Profile Name Base Profile Profile 1 Profile 2 Profile 3 Profile 4 Profile 5 Profile 6
    [Show full text]
  • Highlights of This Issue
    THURSDAY, OCTOBER 4, 1973 WASHINGTON, D.C. HIGHLIGHTS OF THIS ISSUE This listing does not affect the legal status of any document published in this issue. Detailed table of contents appears inside. ECONOMIC STABILIZATION— CLC Phase IV pay and price regulations for certain reg­ istered, practical, and trained nurses (2 documents); effective 10—1—73....................... ........................ 27528, 27529 CLC allows Phase IV price increases for rubber tire and tube products; effective 10—8—73............................. ....... 27528 October 4, 1973— -Pages 27501-27574 METHAQUALONE— Justice Department classifies as Schedule II controlled substance; effective 10—4—73 27516 ARTISTS' PAINTS AND SUPPLIES— Consumer Product Safety Commission exempts from lead content restric­ tions; effective 12—3—73...-......... ........................................ 27514 DEFENSE CONTRACTS— Cost Amounting Standards Board extends disclosure statement filing requirements; effective 4— 1—74............................. ....................................... 27507 PUBLIC ASSISTANCE— HEW proposal on determin­ ing paternity of children receiving aid; comments by 1 1 -5 -7 3 ............................................ -. ............ : ........ 27530 SUGAR— USDA declares and reprorates 1973 quota deficits for Hawaii and Peru................... .................... ........................ 27509 USDA requires no proportionate shares for 1974 sugarbeet crop..--....................... ..............."...................... — 27510 PEANUTS— USDA proposes 1974
    [Show full text]
  • Drug Detection Time Window Chart
    Chesapeake Toxicology Resources Drug Detection Windows Updated as of December, 15th 2014 The length of time that the presence of drugs of abuse in the body can be detected is an important factor in drug screening. The chart below outlines approximate duration times. When interpreting the duration for the presence of drugs of abuse in the body, you must take into consideration variables including the body's metabolism, the subject's physical condition, overall body fluid balance, state of hydration and frequency of usage. Amphetamines Drug Name Metabolite Detection Window Prescription Names Amphetamine 3-5 Days Adderall, Adderall XR, Dexedrine, Spansule, DextroStat MDA 2-5 Days Tenamfetamine MDMA MDA 1-3 Days Adam, Ecstacy Methamphetamine Amphetamine 3-5 Days Desoxyn, Desoxyn Gradument Anti-epileptics Drug Name Metabolite Detection Window Prescription Names Gabapentin 1-5 Days Neurontin, Nupentin, Fanatrex, Gabarone, Gralise Pregablin 1-4 Days Lyrica CHESAPEAKE TOXICOLOGY RESOURCES- DRUG DETECTION TIMETABLE !1 Barbiturates Drug Name Metabolite Detection Window Prescription Names Amobarbital 2-10 Days Amytal, Amylobarbiton, Tuinal Butalbital 4-6 Days Axocet, Axotal, Bucet, Bupap, Butex Forte, Cephadyn, Dolgic, Esgic, Esgic-Plus, Fioricet, Fiorinal, Fiormor, Fiortal, Fortabs, Laniroif, Margesic, Marten-Tab, Medigesic, Phrenilin, Phrenilin Forte, Repan, Sedapap, Tencon, Triad Pentobarbital 2-10 Days Euthasol, Nembutal , Nembutal Sodium, Pentasol Phenobarbital Up to 16 days Antrocol, Barbidonna, Barbita, Bellacane, Bellatal, Bellergal-S, Chardonna-2,
    [Show full text]
  • Treatment Episode Data Set (TEDS) 2003 - 2013
    Treatment Episode Data Set (TEDS) 2003 - 2013 National Admissions to Substance Abuse Treatment Services DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), by Synectics for Management Decisions, Inc. (Synectics), Arlington, Virginia. Work by Synectics was performed under Task Order HHSS283200700048I/HHSS28342001T, Reference No. 283-07-4803 (Cathie Alderks, Task Order Officer). PUBLIC DOMAIN NOTICE All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. ELECTRONIC ACCESS AND COPIES OF PUBLICATION This publication may be downloaded or ordered at store.samhsa.gov. Or call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Room 2-1084 Rockville, Maryland 20857 December 2015 ii TABLE OF CONTENTS List of Tables ...................................................................................................................................v List of Figures ..............................................................................................................................
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • First Reported Case of Lorazepam-Assisted Interview in A
    Hindawi Publishing Corporation Case Reports in Psychiatry Volume 2014, Article ID 346939, 4 pages http://dx.doi.org/10.1155/2014/346939 Case Report First Reported Case of Lorazepam-Assisted Interview in a Young Indian Female Presenting with Dissociative Identity Disorder and Improvement in Symptoms after the Interview Raheel Mushtaq,1,2 Sheikh Shoib,1,2 Tasleem Arif,3 Tabindah Shah,4 and Sahil Mushtaq5 1 ECT Clinic, Postgraduate Department of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir 190010, India 2 Memory Clinic, Postgraduate Department of Psychiatry, Government Medical College, Srinagar 190010, India 3 Post Graduate Department of Dermatology, Government Medical College, Srinagar 190010, India 4 Government Medical College, Srinagar, Jammu and Kashmir 190010, India 5 Acharya Shri Chander College of Medical Sciences, Jammu, India Correspondence should be addressed to Raheel Mushtaq; [email protected] Received 30 May 2014; Revised 17 July 2014; Accepted 18 July 2014; Published 5 August 2014 Academic Editor: Toshiya Inada Copyright © 2014 Raheel Mushtaq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Dissociative identity disorder (DID) is one of the most fascinating disorders in psychiatry. The arduous search to reveal the obscurity of this disorder has led to colossal research in this area over the years. Although drug-assisted interviews are not widely used, they may be beneficial for some patients that do not respond to conventional treatments such as supportive psychotherapy or psychopharmacotherapy. Drug-assisted interviews facilitate recall of memories in promoting integration of dissociative information.
    [Show full text]
  • A Comparison of Drug Use in Driver Fatalities and Similarly Exposed Drivers
    DOT HS-802 488 A COMPARISON OF DRUG USE IN DRIVER FATALITIES AND SIMILARLY EXPOSED DRIVERS Contract No. DOT-HS-4-00941 July 1977 Final Report PREPARED FOR: U.S. DEPARTMENT OF TRANSPORTATION NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION WASHINGTON, D.C. 20590 Document is available to the public through the National Technical Information Service, Springfield, Virginia 22161 This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange. The United States Govern­ ment assumes no liability for its contents or use thereof. Technical Report Documentation Page 1. Report No. 2. Goeemm.nt Accession No. 3. Recipient's Catalog No. DOT HS-802 488 -^. 1. Title and Subtitle 5. Report Date July 1977 A COMPARISON OF DRU^ USE IN DRIVER FATALITIES 6. Performing Organization Code AND SIMILARLY EXPOSED DRIVERS . B. Performing Organization Report No. 7. Authorrs) Robert R. Blackburn, Edward J. Woodhouse 3963-D 9. Performing Organization Name and Address 10. Worb Unit No. (TRAIS) Midwest Research Institute I). Contract at Grant No. 425 Volker Boulevard DOT-HS-4-00941 Kansas City, Missouri 64110 13. Type of Report and Period Covered 12. Sponsoring Agency Name and Address 28 June 1974-25 March 1977 i U.S. Department of Transportation National Highway Traffic Safety Administration Final Report Washington, D.C. 20590 14. Sponsoring Agency Code 15. supplementary Notes 16. Abstract Crash information, urine, blood and bile samples from 900 fatally injured drivers were collected by medical examiners in 22 areas of the country. Ran­ domly selected living drivers were interviewed at times and places of recent fatal crashes in Dallas, Texas, and Memphis, Tennessee and breath, urine, and blood samples were obtained.
    [Show full text]
  • Comparative Enhancing Effects of Phenobarbital, Amobarbital
    [CANCER RESEARCH 35,2884 2890, October 1975] Comparative Enhancing Effects of Phenobarbital, Amobarbital, Diphenylhydantoin, and Dichlorodiphenyltrichloroethane on 2-Acetylaminofluorene-induced Hepatic Tumorigenesis in the Rat Carl Peraino, R. J. Michael Fry, Everett Staffeldt, and John P. Christopher 2 Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois 60439 SUMMARY INTRODUCTION Earlier studies showed that phenobarbital feeding en- In earlier studies (27, 29), the prolonged feeding of hanced hepatic tumorigenesis in rats previously fed 2- phenobarbital to rats that had previously been fed AAF 3 for acetylaminofluorene for a brief period. As part of an a brief period markedly increased the subsequent incidence investigation of the mechanism of this enhancement, the of liver tumors. Using this sequential feeding regime, the present study evaluated the relative enhancing abilities of present study evaluated the relative tumorigenic enhancing amobarbital, diphenylhydantoin, and dichlorodiphenyltri- abilities of other compounds that, to varying degrees, chloroethane (DDT), agents that resemble phenobarbital to resemble phenobarbital in their effects on liver structure and varying degrees in their effects on liver structure and metabolism. The substances examined were amobarbital, metabolism. A comparison of hepatic tumor yields in rats diphenylhydantoin, and DDT. Table 1 compares relevant fed 2-acetylaminofluorene, followed by the test substance characteristics of these agents with those of phenobarbital, (sequential treatment), showed that amobarbital and di- reviewed previously (27, 29). Amobarbital is closest to phenylhydantoin had no enhancing activity, whereas the phenobarbital in structure and, like phenobarbital, alters enhancing effect of DDT was similar to that of phenobarbi- the metabolism of other drugs by the liver. Diphenylhydan- tal.
    [Show full text]
  • A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-Nor-9-Carboxy-Δ9- Tetrahydrocannabinol (THC-A) in Urine
    Application Note Clinical Research A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-nor-9-carboxy-Δ9- tetrahydrocannabinol (THC-A) in Urine Using ESI negative ionization mode and alternating column regeneration Authors Abstract Andre Szczesniewski and Most of the compounds in large drug panels are analyzed using positive ionization Carrie J. Adler mode. However, barbiturates and 11-nor-9-carboxy-Δ9-THC (THC-A) perform better Agilent Technologies, Inc. using electrospray ionization (ESI) in negative mode with the mobile phase pH favorable for negative ionization. This work developed a fast analytical method combining eight barbiturates and THC-A in a single analysis using alternating column regeneration (ACR) to increase sample throughput. Moving the analytes preferring negative ionization into a separate test increases the analytical sensitivity of the compounds, allowing for greater research capabilities. The simple sample preparation techniques used provided rapid analysis, good analytical sensitivity, and quantitation over a wide dynamic range. This analysis used an Agilent 6470 triple quadrupole mass spectrometer with Agilent Jet Stream technology in ESI negative ionization mode and an Agilent Infinity II 1290 UHPLC system. A second pump and 2-position 10-port switching valve were added to facilitate use of the ACR. A 100 µL aliquot of human urine was used for the analysis of barbiturates and THC-A. Chromatographic separation of the analytes was achieved in less than 3 minutes using a gradient method composed of a H2O:acetonitrile mixture with 5 mM ammonium acetate and two Agilent Poroshell 120 EC-C18, 2.1 × 100 mm, 1.9 μm columns.
    [Show full text]
  • Practitioners Guide for Medications in Alcohol and Drug Dependence
    PRACTITIONERS GUIDE FOR MEDICATIONS IN ALCOHOL AND DRUG DEPENDENCE INTRODUCTION It is likely the majority of chemically dependent persons will probably need medications (including both prescriptions and over-the counter) at some point in their recovery. At any time, such medications should only be taken as prescribed by their primary physician in conjunction with their addiction specialist. This Guide is intended to serve as a resource for the recovering chemically dependent person and the medical professional prescribing treatment. It is not meant to be used exclusively or as the sole means for providing advice regarding medications. Indeed, this Guide would be best utilized in conjunction with other concurrent reference materials. Decisions about particular prescription medication(s) should be tailored to the needs of the individual patient under the direction of a health professional. This Guide is not intended to be exhaustive, nor an endorsement of any particular brand name medication. Rather it is intended to provide relevant pharmacological information to the recovering person and health care providers treating those in recovery. GUARDING AGAINST ADDICTION Recovering alcoholics and addicts must be constantly alert to the possibility of triggering a relapse of their disease through the intake of drugs or alcohol. Just as a diabetic needs to be cautious about the intake of sugar, the recovering alcoholic must be sensitive to drugs and the recovering addict must be sensitive to alcohol, and both must be sensitive to other mood-altering drugs, including prescribed and over-the-counter preparations. This Guide is designed to serve as a resource when making decisions regarding what medication(s) to take, as well as a reference tool for those who prescribe medication for persons in recovery.
    [Show full text]
  • Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
    Journal of Clinical Medicine Review Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus Michael E. Reznik 1, Karen Berger 2 and Jan Claassen 1,* 1 Department of Critical Care Neurology, Columbia University Medical Center, New York, NY 10032, USA; [email protected] 2 Department of Pharmacy, Weill Cornell Medical Center, New York, NY 10065, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-212-305-7236; Fax: +1-212-305-2792 Academic Editors: Gretchen M. Brophy and Paul M. Vespa Received: 13 April 2016; Accepted: 16 May 2016; Published: 19 May 2016 Abstract: Status epilepticus that cannot be controlled with first- and second-line agents is called refractory status epilepticus (RSE), a condition that is associated with significant morbidity and mortality. Most experts agree that treatment of RSE necessitates the use of continuous infusion intravenous anesthetic drugs such as midazolam, propofol, pentobarbital, thiopental, and ketamine, each of which has its own unique characteristics. This review compares the various anesthetic agents while providing an approach to their use in adult patients, along with possible associated complications. Keywords: status epilepticus; refractory status epilepticus; IV anesthetics 1. Introduction Refractory status epilepticus (RSE) is defined as ongoing seizures that cannot be controlled with first- and second-line agents and has an incidence ranging from 9% to 43% [1–6]. Some patients fail to respond to third-line therapy, and are considered to have super-refractory SE (SRSE), the true incidence of which is unknown. Both of these are associated with progressively-increasing morbidity and mortality, and expert guidelines advocate early initiation of intravenous anesthetic agents to maximize the chance of seizure cessation while minimizing the risk of long-term sequelae [7].
    [Show full text]